News & Publications

On December 7, 2016, Medical Xpress published an article highlighting the benefits that are associated with the Merkel cell carcinoma antibody test in light of the recently published paper, in the journal Cancer. The test works by measuring the presence of a novel marker - an antibody to a cancer-...

Mark Teich, executive editor of The Skin Cancer Foundation, spoke with Paul Nghiem, MD, PhD, about recent landmark progress in the detection, monitoring and treatment of patients with Merkel cell carcinoma (MCC). Q & A with Dr. Nghiem

7th Edition MCC Staging System Table Stage Primary Tumor Lymph Node Metastasis 0 In situ primary tumor No regional lymph node metastasis No distant metastasis IA Less than or equal to 2 cm maximum tumor dimension Nodes negative by pathologic exam No distant metastasis ...

As of January 2017, the AJCC 8th edition staging system will replace the 7th edition staging system. MCC patients will be categorized by their extent of disease at diagnosis (stage) as summarized in the 8th Edition table (see below) starting in 2017. The 2017 MCC staging system was based on an analy...

Natalie Miller, a University of Washington PhD candidate, successfully defended her thesis on June 1, 2016.

Dr. Nghiem was honored to speak about Merkel cell carcinoma at the the Sidney Kimmel Comprehensive Cancer Center's 2016 Director's Visiting Lecture Series on April 21 and April 22, 2016.

Dr. Nghiem was pleased and honored to be the keynote speaker at the 6th Annual Harley Haynes Lectureship and Symposium at Harvard Medical School on March 21, 2016. Dr. Haynes had an enormous influence on Dr. Nghiem’s career in terms of becoming a dermatologist and focusing on Merkel cell carcinoma...

The MMIG (Merkel cell carcinoma Multicenter Interest Group) had its annual meeting in Washington, DC, at the American Academy of Dermatology.

Dr. Nghiem and Dr. Bhatia spoke at the 2015 European Cancer Congress in Vienna, Austria.  

Recognizing that Merkel polyomavirus-negative MCCs are different and not well understood, the family and friends of Janet Canning have decided to support research that will help us to recognize, understand and manage this distinct and often aggressive sub-type of MCC.